Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
$206.12M
Mr. Faheem Hasnain
185.00
San Diego, CA
Feb 08, 2019
-4.80
$-0.19
1.92
8.21
-78.78%
-2.51
0.00
2.49
1.98
8.21
-21.65%
-117.33%
Similar stocks (16)
Akero Therapeutics, Inc.
AKRO
4D Molecular Therapeutics, Inc.
FDMT
Terns Pharmaceuticals, Inc.
TERN
Stoke Therapeutics, Inc.
STOK
Replimune Group, Inc.
REPL
Alector, Inc.
ALEC
Inozyme Pharma, Inc.
INZY
Biomea Fusion, Inc.
BMEA
Black Diamond Therapeutics, Inc.
BDTX
Amylyx Pharmaceuticals, Inc.
AMLX
Acumen Pharmaceuticals, Inc.
ABOS
Nuvectis Pharma, Inc.
NVCT
X4 Pharmaceuticals, Inc.
XFOR
Kronos Bio, Inc.
KRON
Passage Bio, Inc.
PASG
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (13)
Schwab U.S. Small-Cap ETF
SCHA
0.0053910532%
Schwab U.S. Broad Market ETF
SCHB
5.357605e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Health Care Index Fund
VHT
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (16)
Akero Therapeutics, Inc.
AKRO
4D Molecular Therapeutics, Inc.
FDMT
Terns Pharmaceuticals, Inc.
TERN
Stoke Therapeutics, Inc.
STOK
Replimune Group, Inc.
REPL
Alector, Inc.
ALEC
Inozyme Pharma, Inc.
INZY
Biomea Fusion, Inc.
BMEA
Black Diamond Therapeutics, Inc.
BDTX
Amylyx Pharmaceuticals, Inc.
AMLX
Acumen Pharmaceuticals, Inc.
ABOS
Nuvectis Pharma, Inc.
NVCT
X4 Pharmaceuticals, Inc.
XFOR
Kronos Bio, Inc.
KRON
Passage Bio, Inc.
PASG
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (13)
Schwab U.S. Small-Cap ETF
SCHA
0.0053910532%
Schwab U.S. Broad Market ETF
SCHB
5.357605e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Health Care Index Fund
VHT
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%